WEBULL
WebtradeDownload

Terumo (TSE:4543) Is Up 12.6% After One-Off Tariff Boost Lifts Earnings Guidance

Simply Wall St · 1d ago
  • In early August 2026, Terumo Corporation raised its full-year earnings guidance for the fiscal year ending March 31, 2027, while reporting first-quarter revenue of ¥311,810 million and net income of ¥70,426 million, both higher than a year earlier.
  • The guidance upgrade was driven by a refund of U.S. tariffs and settlement proceeds, offering a one-off boost to profits that sits alongside underlying sales growth.
  • We’ll now examine how this tariff-driven upward earnings revision could influence Terumo’s existing investment narrative and longer-term earnings profile.

AI is about to change healthcare. These 6 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Terumo Investment Narrative Recap

To own Terumo, you need to believe its medical device portfolio can keep growing volumes and pricing despite tariffs, procurement pressure, and rising costs. The tariff refund and settlement-driven guidance upgrade lift near term earnings, but they do not remove the key risk that recurring tariffs and hospital buyers may push back on future price increases, which could matter more for margins than this one off boost.

The most relevant announcement here is the August 7 guidance revision, which lifted forecast profit attributable to owners of parent from ¥165,300 million to ¥193,100 million on unchanged revenue of ¥1,239,000 million. That gap largely reflects tariff refunds and settlement income, so I see it as a helpful but temporary earnings support, rather than a change in Terumo’s core volume and pricing catalysts across cardiovascular, neurovascular, and blood solutions.

Yet behind this upgraded guidance, there is a risk investors should be aware of around Terumo’s exposure to future tariff and procurement pressures that could...

Read the full narrative on Terumo (it's free!)

Terumo's narrative projects ¥1,439.7 billion revenue and ¥216.3 billion earnings by 2029. This requires 6.7% yearly revenue growth and about a ¥51.8 billion earnings increase from ¥164.5 billion today.

Uncover how Terumo's forecasts yield a ¥3075 fair value, a 15% upside to its current price.

Exploring Other Perspectives

TSE:4543 1-Year Stock Price Chart
TSE:4543 1-Year Stock Price Chart

Some of the most cautious analysts were already assuming revenue of about ¥1,340,900 million and earnings of roughly ¥195,600 million by 2029, so this tariff driven earnings uplift could challenge their more pessimistic view that global procurement rules and price pressure will steadily grind down Terumo’s margins, and it is worth weighing that against your own expectations.

Explore 2 other fair value estimates on Terumo - why the stock might be worth just ¥3075!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Terumo research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Terumo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Terumo's overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.